Lund, Sweden

Hans Lönn

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2008-2013

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: **Inventor Hans Lönn: Pioneering Innovations in Neutrophil Elastase Inhibitors**

Introduction

Hans Lönn, an accomplished inventor based in Lund, Sweden, has made significant contributions to the field of pharmacology through his innovative inventions. With a total of six patents to his name, his research focuses on novel compounds that play crucial roles in therapeutic applications.

Latest Patents

Among his latest patents is a remarkable invention involving 2-pyrazinone derivatives which are designed as inhibitors of neutrophil elastase. This invention provides unique compounds listed in the specification along with pharmaceutically acceptable salts and specific forms thereof. These compounds are essential in therapeutic contexts, particularly for human health as neutrophil elastase inhibitors. Notable examples include the compound 6-[1-(4-Cyanophenyl)-1H-pyrazol-5-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide and its related salt and form, which reveal progressive methods for their preparation and applications in pharmaceutical compositions.

Career Highlights

Hans Lönn has established his career at AstraZeneca AB, a leading global biopharmaceutical company, where he has made substantial advancements in drug development and innovation. His work emphasizes the importance of research and practical applications in the pharmaceutical industry, showcasing his commitment to pursuing groundbreaking inventions.

Collaborations

Throughout his career, Hans has collaborated with notable colleagues, including Peter Hansen and Antonios Nikitidis. These collaborations represent a network of expertise and shared knowledge that have fueled advancements in their respective fields, allowing for synergistic research and innovative solutions.

Conclusion

Hans Lönn continues to be an influential figure in the realm of pharmacology and drug development. His dedication to inventing novel compounds and understanding their therapeutic potentials highlights the importance of innovation in addressing health challenges. As he progresses in his career, Lönn's contributions are likely to have a lasting impact on the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…